Alnylam To Present Full 18-Month Results From The HELIOS-A Phase 3 Study Of Vutrisiran At The Société Francophone Du Nerf Périphérique Annual Meeting

Press/Media

Period14 Jan 2022

Media coverage

15

Media coverage